Investigation of intravenous azithromycin treatment safety when reducing solvent for intensive care unit patients

Yuto Haruki, Hideharu Hagiy, Akiko Sakuma, Mai Haruki, Yasue Oka, Tetsuhiro Sugiyama, Yasuhiro Kawakami, Sachiyo Kondo

Research output: Contribution to journalComment/debate

Abstract

Intravenous azithromycin (AZM) was approved for use in December 2011 in Japan. In general, intravenous AZM injections are diluted to 1 mg/mL, with a total infusion volume of 500 mL to avoid phlebitis. Patients in intensive care units (ICUs) require small infusion volumes. We retrospectively evaluated the total AZM infusion volume in 65 ICU patients receiving AZM treatment from December 2011 to August 2014. Thirteen patients (20.0%) received a reduced volume [100 mL (5 mg/mL) or 250 mL (2 mg/mL)] using an infusion pump over 2 h. No peripheral phlebitis was observed in any patient. Based on this result, it is assumed that AZM can be safely administered to ICU patients even though the volume of solvent is reduced. AZM is widely recommended for the treatment of community-acquired respiratory infections and is used in patients with severe infections. Further investigation is required in additional patients to understand the effects of AZM volume reduction in greater detail.

Original languageEnglish
Pages (from-to)987-990
Number of pages4
JournalYakugaku Zasshi
Volume135
Issue number8
DOIs
Publication statusPublished - Aug 1 2015

Fingerprint

Azithromycin
Intensive Care Units
Safety
Phlebitis
Therapeutics
Community-Acquired Infections
Infusion Pumps
Intravenous Injections
Respiratory Tract Infections
Japan
Infection

Keywords

  • Azithromycin
  • Intensive care unit
  • Peripheral phlebitis
  • Safety
  • Volume of solvent

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Investigation of intravenous azithromycin treatment safety when reducing solvent for intensive care unit patients. / Haruki, Yuto; Hagiy, Hideharu; Sakuma, Akiko; Haruki, Mai; Oka, Yasue; Sugiyama, Tetsuhiro; Kawakami, Yasuhiro; Kondo, Sachiyo.

In: Yakugaku Zasshi, Vol. 135, No. 8, 01.08.2015, p. 987-990.

Research output: Contribution to journalComment/debate

Haruki, Y, Hagiy, H, Sakuma, A, Haruki, M, Oka, Y, Sugiyama, T, Kawakami, Y & Kondo, S 2015, 'Investigation of intravenous azithromycin treatment safety when reducing solvent for intensive care unit patients', Yakugaku Zasshi, vol. 135, no. 8, pp. 987-990. https://doi.org/10.1248/yakushi.15-00003
Haruki, Yuto ; Hagiy, Hideharu ; Sakuma, Akiko ; Haruki, Mai ; Oka, Yasue ; Sugiyama, Tetsuhiro ; Kawakami, Yasuhiro ; Kondo, Sachiyo. / Investigation of intravenous azithromycin treatment safety when reducing solvent for intensive care unit patients. In: Yakugaku Zasshi. 2015 ; Vol. 135, No. 8. pp. 987-990.
@article{81b08779d7f849c1b6091dfe741c8832,
title = "Investigation of intravenous azithromycin treatment safety when reducing solvent for intensive care unit patients",
abstract = "Intravenous azithromycin (AZM) was approved for use in December 2011 in Japan. In general, intravenous AZM injections are diluted to 1 mg/mL, with a total infusion volume of 500 mL to avoid phlebitis. Patients in intensive care units (ICUs) require small infusion volumes. We retrospectively evaluated the total AZM infusion volume in 65 ICU patients receiving AZM treatment from December 2011 to August 2014. Thirteen patients (20.0{\%}) received a reduced volume [100 mL (5 mg/mL) or 250 mL (2 mg/mL)] using an infusion pump over 2 h. No peripheral phlebitis was observed in any patient. Based on this result, it is assumed that AZM can be safely administered to ICU patients even though the volume of solvent is reduced. AZM is widely recommended for the treatment of community-acquired respiratory infections and is used in patients with severe infections. Further investigation is required in additional patients to understand the effects of AZM volume reduction in greater detail.",
keywords = "Azithromycin, Intensive care unit, Peripheral phlebitis, Safety, Volume of solvent",
author = "Yuto Haruki and Hideharu Hagiy and Akiko Sakuma and Mai Haruki and Yasue Oka and Tetsuhiro Sugiyama and Yasuhiro Kawakami and Sachiyo Kondo",
year = "2015",
month = "8",
day = "1",
doi = "10.1248/yakushi.15-00003",
language = "English",
volume = "135",
pages = "987--990",
journal = "Yakugaku Zasshi",
issn = "0031-6903",
publisher = "Pharmaceutical Society of Japan",
number = "8",

}

TY - JOUR

T1 - Investigation of intravenous azithromycin treatment safety when reducing solvent for intensive care unit patients

AU - Haruki, Yuto

AU - Hagiy, Hideharu

AU - Sakuma, Akiko

AU - Haruki, Mai

AU - Oka, Yasue

AU - Sugiyama, Tetsuhiro

AU - Kawakami, Yasuhiro

AU - Kondo, Sachiyo

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Intravenous azithromycin (AZM) was approved for use in December 2011 in Japan. In general, intravenous AZM injections are diluted to 1 mg/mL, with a total infusion volume of 500 mL to avoid phlebitis. Patients in intensive care units (ICUs) require small infusion volumes. We retrospectively evaluated the total AZM infusion volume in 65 ICU patients receiving AZM treatment from December 2011 to August 2014. Thirteen patients (20.0%) received a reduced volume [100 mL (5 mg/mL) or 250 mL (2 mg/mL)] using an infusion pump over 2 h. No peripheral phlebitis was observed in any patient. Based on this result, it is assumed that AZM can be safely administered to ICU patients even though the volume of solvent is reduced. AZM is widely recommended for the treatment of community-acquired respiratory infections and is used in patients with severe infections. Further investigation is required in additional patients to understand the effects of AZM volume reduction in greater detail.

AB - Intravenous azithromycin (AZM) was approved for use in December 2011 in Japan. In general, intravenous AZM injections are diluted to 1 mg/mL, with a total infusion volume of 500 mL to avoid phlebitis. Patients in intensive care units (ICUs) require small infusion volumes. We retrospectively evaluated the total AZM infusion volume in 65 ICU patients receiving AZM treatment from December 2011 to August 2014. Thirteen patients (20.0%) received a reduced volume [100 mL (5 mg/mL) or 250 mL (2 mg/mL)] using an infusion pump over 2 h. No peripheral phlebitis was observed in any patient. Based on this result, it is assumed that AZM can be safely administered to ICU patients even though the volume of solvent is reduced. AZM is widely recommended for the treatment of community-acquired respiratory infections and is used in patients with severe infections. Further investigation is required in additional patients to understand the effects of AZM volume reduction in greater detail.

KW - Azithromycin

KW - Intensive care unit

KW - Peripheral phlebitis

KW - Safety

KW - Volume of solvent

UR - http://www.scopus.com/inward/record.url?scp=84938520669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938520669&partnerID=8YFLogxK

U2 - 10.1248/yakushi.15-00003

DO - 10.1248/yakushi.15-00003

M3 - Comment/debate

C2 - 26234357

AN - SCOPUS:84938520669

VL - 135

SP - 987

EP - 990

JO - Yakugaku Zasshi

JF - Yakugaku Zasshi

SN - 0031-6903

IS - 8

ER -